Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003513582 | SCV004291763 | likely pathogenic | Deficiency of hydroxymethylglutaryl-CoA lyase | 2023-08-04 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Asp42 amino acid residue in HMGCL. Other variant(s) that disrupt this residue have been observed in individuals with HMGCL-related conditions (PMID: 9463337, 18080783), which suggests that this may be a clinically significant amino acid residue. Experimental studies have shown that this missense change affects HMGCL function (PMID: 9463337). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt HMGCL protein function. This missense change has been observed in individuals with HMG-CoA lyase deficiency (PMID: 9463337, 19177531). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 42 of the HMGCL protein (p.Asp42Gly). |